Ipsen Group

David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020.

Prior to joining Ipsen, David was CEO of Sanofi Pasteur Vaccines. During his tenure, he piloted a successful worldwide growth strategy via acquisitions and licensing deals.

David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region.

David has served on the board of the Global Alliance for Vaccines and Immunization (GAVI), chaired the Steering Committee of IFPMA and has strong connections with global organizations, including the WHO, UNICEF, the Bill & Melinda Gates Foundation, as well as American health agencies, including BARDA and the NIH.

David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.

Bartosz (Bartek) Bednarz, DDS, is Executive Vice President, Head of Global Product and Portfolio Strategy at Ipsen, which covers Global Franchises, Global Value and Access, Global Policy and Global Strategic Business Excellence. Bartosz joined Ipsen in 2017 and has 20+ years of pharmaceutical leadership experience.

Before assuming an EVP role, Bartosz successfully led Ipsen’s Oncology franchise. Prior to that, he held global leadership roles at AstraZeneca and Novartis. At AstraZeneca, where Bartosz spent seven years, he started as Country President and later led new launches in Oncology as well as Oncology Commercial Operations at a global level while based in Cambridge (UK). At Novartis, Bartosz held various commercial leadership roles at local, regional and international levels around the world, including Poland, Spain, Switzerland and Canada. He has worked across multiple therapeutic areas and is very passionate about all three TAs at Ipsen: Oncology, Rare Disease and Neuroscience.

Bartosz Bednarz is a Doctor of Dental Medicine. He obtained his diploma with honors at the Medical University of Pomerania in Poland.

Dominique Bery joined Ipsen in April 2017.

Dominique spent the previous 18 years with McKinsey & Company, where she was elected Partner in 2010. Dominique co-led the Pharmaceuticals and Medical Products Practice in Europe and served multiple pharmaceutical and biotech companies. She also worked with diagnostics companies, hospitals, payors, ministries of health, patient associations, and public health organizations, gaining extensive experience in the healthcare industry.

Located in Paris and Washington, Dominique led many company-wide transformation projects across Europe, US and Africa, working hand in hand with management and their teams. She supported clients to set their strategic priorities at corporate, business unit, and therapeutic area level, and she worked with a number of brand teams to accelerate brand performance. She brings a truly cross-functional perspective, having worked closely with most functions in pharmaceutical companies. In parallel, she initiated the creation of a community of women executives in France, focused on developing the capabilities of women executives on key business topics such as innovation, leadership in transformation, business model disruption.

Dominique is a graduate from ESSEC and holds a Masters in Business Administration from Harvard Business School.

François Garnier was appointed Executive Vice-President, General Counsel in December 2014.

François began his career in 1989 at Servier S.A. as International Contracts Manager, and remained with the company until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. François continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.

Francois joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (ex-US) for Pfizer Inc. from January 2014.

A student from the IEP in Paris, Francois graduated from the University of Panthéon-Assas prior to working in the legal departments of a number of pharmaceutical groups.

Benoît Hennion has been Executive Vice-President, Consumer Healthcare since March 2017.

Benoît joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Business Unit Head, and subsequently in 2011, General Manager France leading both Specialty Care and Consumer Healthcare. In 2014, Benoît was appointed Vice President Asia-Pacific Specialty Care, based in Seoul, Korea for three years. Benoît gained his MBA degree at ESSEC (Paris, France). Before joining Ipsen, he started his career at Société Générale in the Czech Republic and then served for six years in the Paris office of Roland Berger Strategy Consultants.

Steven Hildemann, M.D., PhD, is Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs at Ipsen.

Prior to joining Ipsen, Dr.Hildemann held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck. He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.

Dr Hildemann is board certified in internal medicine and cardiology with broad clinical training across internal medicine including medical oncology, gastroenterology, rheumatology and pulmonary oncology at university hospitals in Munich, Germany. Throughout his career, he has engaged in part-time clinical practice, late-stage pharmaceutical research and medical teaching. Dr. Hildemann received his MD-PhD at the Albert Ludwig University of Freiburg, Germany, where he continues to serve as an adjunct Professor of Medicine.

Dominique Laymand was appointed Executive Vice-President, Chief Ethics and Compliance Officer in October 2017.
Dominique Laymand joined Ipsen in 2015 as Senior Vice-President, Chief Ethics and Compliance Officer.

Dominique is in charge of Ethics & Compliance strategy for the Ipsen Group, the deployment of the Global Ethics & Compliance program and the organization of this department. The Global Ethics & Compliance program is based on an integrated approach to prevention and management of operational risks, as well as on strong principles of integrity and ethics in the conduct of business.

Previously Dominique served as Vice-President Ethics & Compliance at Bristol Myers Squibb, setting up and managing the Ethics & Compliance Europe, Middle East, Africa, Turkey and Russia program.

Dominique also chairs the committee of compliance at the European Federation of Pharmaceutical Industries and Associations (EFPIA) and also at the French Association of Pharmaceutical Industries (Leem).

Dominique is the president of ETHICS, an association which includes international professionals in Ethics and Compliance working in the healthcare sector.

Aymeric Le Chatelier was appointed Executive Vice-President, Group Chief Financial Officer in November 2014.

Aymeric Le Chatelier, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and member of the Management Board.

Aymeric served as interim Chief Executive Officer of the Group from 1 January 2020 until David Loew was appointed Chief Executive Officer on 1 July 2020.

Philippe Lopes-Fernandes joined Ipsen as Executive Vice President and Chief Business Officer in 2020. With more than 20 years of leadership and expertise in global business development and acquisitions within the pharmaceutical industry, Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of Oncology, Neuroscience and Rare Diseases. He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America.

Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management. Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in Germany, France, Portugal, Switzerland and the United States.

Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies. He is based in Cambridge, Massachusetts.

Howard Mayer, M.D., is Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals. Dr. Mayer joined Ipsen in 2019 from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.

Previously, Dr. Mayer served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.

Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.

Régis Mulot joined Ipsen Pharma, in March 2018, as Executive Vice President, Chief Human Resources Officer

Régis Mulot joins Ipsen from Staples Inc., the global specialty retail and e-commerce company, where he served as Executive Vice-President, Chief Human Resources Officer, leading a global team of over 600 professionals. Prior to his career with Staples (2009-18), Mr Mulot held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91).

Mr Mulot served on the Board of Trustees, Simmons College (Boston M.A.); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Founder and former chair of the French-American HR Forum since 2016-2018. He has been Co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit between 2014 and 2018, and is a Gartner CHRO Leadership Board member since 2017.

Mr Mulot holds a DESS Entreprises Publiques (Master in Public Administration) from Paris XI-Sud in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Paris II–Panthéon-Assas, and is a Beta Gamma Sigma honoree from the Simmons College Chapter.

Dr Aidan Murphy was appointed Executive Vice-President, Technical Operations, effective 1st January 2018. Dr Murphy has more than 25 years experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held a number of manufacturing leadership roles in many countries.

Since 2014 Dr Murphy has held the position of Senior Vice President Biologics Development and Manufacturing at Ipsen. Also during his tenure at Ipsen, he has led the manufacturing sites of Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a PhD in organic chemistry from Trinity College, Dublin.

Since joining Ipsen in February 2018 as the North America Chief Executive Officer, Richard has been responsible for expanding and driving continued growth in both the U.S. and Canadian markets across key therapeutics areas of oncology, neuroscience and rare diseases. Richard has more than 25 years of global biopharmaceutical industry experience with notable achievements for his leadership, vision, and exceptional execution in growing businesses, both in the US and internationally. He has a patient-focused mindset and a proven track record of successfully building high-performing, customer-centric teams. At Ipsen, Richard serves as a member of the Executive Leadership Team and chairs the Global Business Operations leadership team.

Prior to joining Ipsen, Richard had a 10-year career at Amgen where he held varying leadership positions across Europe and North America, including, Vice President and General Manager of Amgen’s U.S. Oncology Business Unit. Prior to that, he was the Vice President of Marketing for its U.S. Oncology Business, Vice President and General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to joining Amgen, Richard held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic as well as positions in marketing and market access. Richard also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.

Richard serves as a member of the BIO Health Section Governing Board (HSGB), the Karyopharm Therapeutics Board, Boston Police Athletic League Board and as an interim director on the PhRMA Board of Directors.

Richard earned his undergraduate degree in Commerce from the University of Saskatchewan, Canada, and his MBA from the University of Toronto, Canada.

Patrice Zagame was appointed Executive Vice President, Specialty Care International on September 2nd 2020. He will be responsible for all regions except the US and Canada. Patrice joined Ipsen on May 2020 in the role of Senior Vice President, Head of International for the Specialty Care organization.

Prior to joining Ipsen, Patrice was based in Brazil, where he worked as an investor, board member and entrepreneur. Patrice also previously held the roles of President & Executive VP Intercontinental at Baxalta. Before that, Patrice worked as Country President at Sanofi and Novartis in France, Brazil, Spain and Venezuela.

He began his career at Rhone Poulenc Rorer as assistant product manager, later moving to a district director role. He has also been Business Franchise Manager and Head of Oncology at Glaxo Wellcome. Patrice holds a Master’s in Business Administration (MBA) from the International Institute for Management Development in Switzerland and a doctorate in medicine from the Sorbonne University, Pierre and Marie Curie in France.